Table 1.
Kidney pathology in rats injected with anti-AQP-4 antibody containing or control Ig preparations in the presence or absence of AQP-4- or control antigen-specific T cells
| Treatment | Rats studied/rats with T cells around collecting ducts | Numbers of collecting ducts surrounded by T cells | Numbers of collecting ducts infiltrated by T cells | Numbers of collecting ducts surrounded by macrophages | Numbers of collecting ducts infiltrated by macrophages |
|---|---|---|---|---|---|
| AQP-4207–232 spec. T cells + NMO-IgG | 6/5 | 95.8 ± 106.6a,c | 26.8 ± 23.4a,c | 86.0 ± 72.8a | 23.5 ± 18.4a |
| AQP-4207–232 spec. T cells + Subcuvia | 3/2 | 3.0 ± 4.4 | 0.0 ± 0.0 | 4.0 ± 4.6 | 0.7 ± 0.6 |
| AQP-4207–232 spec. T cells + 0 | 3/2 | 4.0 ± 3.5 | 1.0 ± 1.0 | 8.7 ± 7.8 | 2.0 ± 1.7 |
| AQP-4296–304 spec. T cells + 0 | 5/5 | 7.6 ± 6.7 | 2.4 ± 2.3 | 22.4 ± 19.6 | 4.4 ± 5.5 |
| AQP-4296–304 spec. T cells + NMO-IgG | 1/1 | 151 | 41 | 283 | 73 |
| MBP-spec. T cells + 0 | 5/0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.6 ± 1.3 | 0.0 ± 0.0 |
| MBP-spec. T cells + NMO-IgG | 4/0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 2.8 ± 3.9 | 0.2 ± 0.4 |
| 0 + NMO-IgG | 5/5 | 25.2 ± 19.6b | 3.6 ± 3.3b | 125.8 ± 36.5b | 41 ± 7.9b |
| OVA-spec. T cells + NMO-IgG | 3/3 | 17.3 ± 5.9 | 3.0 ± 3.0 | 67.3 ± 25.5 | 11.7 ± 2.3 |
| OVA-spec. T + Subcuvia | 3/1 | 0.7 ± 1.2 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.3 ± 0.6 |
| 0 + Subcuvia | 4/4 | 1.5 ± 3 | 2 ± 2.2 | 0,0 ± 0.0 | 0.25 ± 0.5 |
| 0 + J1 | 2/2 | 26.4 ± 31.3 | 11.8 ± 12.4 | 164.8 ± 230.0 | 21.4 ± 27.8 |
| 0 + J3 | 2/2 | 3.0 ± 1.4 | 1.0 ± 0.0 | 3.5 ± 4.9 | 2.5 ± 0.7 |
| 0 + J4 | 2/1 | 1.0 ± 1.4 | 0.0 ± 0.0 | 1.0 ± 1.4 | 1.5 ± 0.7 |
| 0 + J6 | 2/1 | 2.0 ± 2.83 | 0.0 ± 0.0 | 4.5 ± 0.7 | 0.5 ± 0.7 |
| 0 + J7 | 2/1 | 0.5 ± 0.7 | 0.0 ± 0.0 | 1.0 ± 1.4 | 0.0 ± 0.0 |
| 0 + J8 | 2/2 | 2.5 ± 2.1 | 0.5 ± 0.7 | 2.5 ± 3.5 | 1.5 ± 2.1 |
| 0 + J9 | 2/0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
The anti-aquaporin-4 antibody containing human neuromyelitis optica immunoglobulin preparation “NMO-IgG” derived from the AQP-4 antibody+ NMO patient J0. We further used human immunoglobulin preparations from patients J1 (AQP-4 antibody + NMO patient), J3 and J4 (AQP-4 antibody- NMO patients), J6 and J7 (AQP-4 antibody- multiple sclerosis patients), and J8 and J9 (AQP-4 antibody-control patients). Information about age, sex, disease, disease duration, magnetic resonance imaging and antibody status of these patients has already been described [5]
aStatistically significant when compared to combined data of AQP-4207–232 spec. T cells + Subcuvia and AQP-4207–232 spec. T cells + 0, bStatistically significant when compared with 0 + Subcuvia
c1/6 animals did not show any evidence for peri-ductal inflammation. Statistically significant differences between AQP-4207–232 spec. T cells + NMO-IgG vs 0 + NMO-IgG were seen when this animal was excluded